Updated:
BIOXYTRAN, INC
Bioxytran is a clinical-stage biotech led by David Platt, developing oxygen-carrying drugs for stroke and brain hypoxia.
BIOXYTRAN, INC
Bioxytran was founded as a life sciences company focused on solving oxygen-deprivation at the cellular level. The firm's core technology, a proprietary carbohydrate-based drug platform, aims to mimic hemoglobin in transporting oxygen to tissues that conventional circulation cannot reach. The company's pipeline is anchored by BXT-25, a brain-tropic oxygen carrier in clinical trials for acute ischemic stroke. Bioxytran also pursues applications in wound healing and viral deactivation, including a program that explored a glycan-binding agent for COVID-19. Its development model relies on contract research organizations and university collaborations rather than large internal labs. With no disclosed institutional AUM, Bioxytran functions as an operating company rather than an investment vehicle. Its balance sheet reflects the micro-cap biotech norm — capital raised through equity financings and convertible instruments. The firm's public filings show David Platt and Michael Sheikh as the primary controlling officers, with Sheikh managing the financial structure that has sustained operations through multiple dilutive rounds. The unusual structural element for this company is its OTC listing, which provides a liquidity mechanism rarely used by clinical-stage drug developers. Rather than building toward a traditional IPO, Bioxytran has operated as a public entity since the earliest phases of its science, creating an entry point for retail investors in a space typically reserved for accredited venture capitalists.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Principals
David Platt
Chief Executive Officer
Michael Sheikh
Chief Financial Officer
Sector focus
Frequently asked questions
What is Bioxytran's lead drug candidate?
The lead asset is BXT-25, a brain-tropic oxygen carrier designed to treat acute ischemic stroke by transporting oxygen across the blood-brain barrier. The firm has also explored additional applications for its carbohydrate-based platform in wound care and antiviral indications.
How is Bioxytran funded as a clinical-stage company?
Bioxytran does not operate with a traditional venture capital backing. It has remained publicly traded on OTC markets and raises capital through equity financings and convertible instruments, making its financial structure atypical for a pre-revenue biotech.
Who controls decision-making at Bioxytran?
David Platt serves as CEO and appears to direct the scientific strategy, while Michael Sheikh acts as CFO, overseeing the financial architecture. Public filings list them as the primary officers, suggesting concentrated operational control.
Does Bioxytran have any partnership with major pharmaceutical companies?
There is no public record of a partnership with a major pharmaceutical firm. Bioxytran's disclosed collaborations have primarily involved contract research organizations and academic institutions for its clinical and preclinical work.
Is Bioxytran structured as a venture-backed private company?
No. Bioxytran is publicly traded on OTC markets, a structural anomaly for a clinical-stage biotech. This allows retail investors to participate directly, bypassing the venture capital gatekeepers that typically fund early drug development.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: